Corcept Therapeutics Incorporated
Financials
Valuation Metrics
Corcept Therapeutics Incorporated's Market Cap is $8.64B. At end of 2025 it was $3.61B. Ranked #961 of 3,116 in US market (top 31%), #310 of 1,472 on NASDAQ (top 21%), #48 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.64B | US#961/3,116 Sec#48/265 |
| Revenue | $831M | US#1,960/3,116 Sec#58/265 |
| Net Income | $55M | US#1,838/3,116 Sec#63/265 |
| Total Assets | $889M | US#2,523/3,116 Sec#111/265 |
| Net Assets | $706M | US#1,992/3,116 Sec#86/265 |
| Employees | 730 | US#2,107/3,116 Sec#68/265 |
| Value | ||
| P/E | 157.42x | US#2,155/3,116 Sec#73/265 |
| P/B | 12.24x | US#2,692/3,116 Sec#199/265 |
| P/S | 10.40x | US#2,720/3,116 Sec#121/265 |
| EV/EBITDA | 296.65x | US#2,484/3,116 Sec#85/265 |
| FCF Yield | 1.24% | US#2,151/3,116 Sec#77/265 |
| Profitability | ||
| ROE | 7.78% | US#1,608/3,116 Sec#53/265 |
| ROA | 6.18% | US#896/3,116 Sec#49/265 |
| Op. Margin | 0.77% | US#2,280/3,116 Sec#78/265 |
| Revenue Growth | 16.02% | US#844/3,116 Sec#80/265 |
| Earnings Growth | -58.66% | US#1,735/3,116 Sec#46/265 |
| Financial Health | ||
| Debt Ratio | 25.92% | US#288/3,116 Sec#93/265 |
| Total Debt | $9M | US#2,831/3,116 Sec#199/265 |
| FCF | $107M | US#1,705/3,116 Sec#61/265 |
| Cash | $111M | US#2,162/3,116 Sec#163/265 |
| Current Ratio | 2.86x | US#825/3,116 Sec#195/265 |
| Net Debt/EBITDA | -3.53x | US#95/3,116 Sec#6/265 |
| Performance | ||
| 1Y Return | 9.57% | US#1,203/3,116 Sec#112/265 |
| 1M Return | -30.74% | US#2,971/3,116 Sec#245/265 |
| From 52W High | -36.30% | US#2,084/3,116 Sec#139/265 |
| 1Y MDD | -63.46% | US#2,811/3,116 Sec#217/265 |
| Trading | ||
| Volume | 1,293,172 shares | US#1,478/3,116 Sec#150/265 |
| Trading Value | $104M | US#932/3,116 Sec#55/265 |
| Per Share | ||
| EPS | $0.51 | US#1,868/3,116 Sec#58/265 |
| BPS | $6.57 | US#2,130/3,116 Sec#107/265 |
Company Info
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.